Your session is about to expire
← Back to Search
High-Dose Carfilzomib Combo for Multiple Myeloma
Study Summary
This trial is testing whether carfilzomib, when given in high doses and alongside other drugs, is safe for patients and what the best tolerated dose is. The trial is also testing how much myeloma cells are left in the body after treatment (known as minimal residual disease or MRD).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 126 Patients • NCT03029234Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I agree to use a latex condom during sex with a female partner.I do not have uncontrolled health issues or recent major surgery.My condition has caused damage to my organs or triggered a significant event.You must meet certain requirements for lab tests and medical scans.You have a specific type of disease that can be measured using certain criteria within the last 4 weeks.I am using birth control and have had a recent negative pregnancy test.My blood and liver tests are within normal ranges.I have been recently diagnosed with multiple myeloma.I can take care of myself and am up and about more than half of my waking hours.I have received more than one cycle of treatment for multiple myeloma.I am 18 years old or older.I can safely undergo treatments to prevent blood clots.I have followed the required break period after my last treatment.
- Group 1: Carfilzomib, Lenalidomide, and Dexamethasone
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have there been other scientific investigations concerning Carfilzomib?
"At present, 705 ongoing studies are utilizing Carfilzomib with 167 of them being in their final phase. Most experiments occur near Joliet, Illinois but there are 25 542 other sites also conducting trials on the drug."
To what maladies is Carfilzomib typically administered?
"Carfilzomib is usually used to treat ophthalmic and sympathetic disorders. Furthermore, this medication has been proven effective against various other illnesses such as branch retinal vein occlusion, macular edema and diseases requiring a minimum of two prior systemic chemotherapy regimens."
What is the current size of the participant pool for this experiment?
"At this moment, applications are not being accepted for this clinical trial; the first posting was on October 1st 2016 and the last update occured November 18th 2022. If you're looking to participate in other trials involving multiple myeloma or Carfilzomib, there are currently 807 and 705 studies respectively recruiting patients."
Are any North American locations participating in this investigation?
"There are seven medical sites accepting patients for this study, such as Memorial Sloan Kettering Monmouth in Middletown and Memorial Sloan Kettering Bergen in Montvale. Additionally, there are four other locations that can accommodate trial participants."
Are there still vacancies available for inclusion in this experiment?
"According to clinicaltrials.gov, this particular trial, which was initially posted on October 1st 2016 and last updated on November 18th 2022 is not currently recruiting patients. Nevertheless, there are 1512 other trials in progress that may be a viable option for individuals seeking out medical treatments."
Share this study with friends
Copy Link
Messenger